4-(4-chloro-benzyl)-piperidin-4-ol | 83072-21-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(4-chloro-benzyl)-piperidin-4-ol
• 英文别名: 4-(4-chlorobenzyl)-piperidin-4-ol；4-(4-chlorobenzyl)piperidin-4-ol；4-[(4-Chlorophenyl)methyl]piperidin-4-ol
• CAS: 83072-21-3
• 化学式: C₁₂H₁₆ClNO
• mdl: MFCD16313784
• 分子量: 225.718
• InChiKey: TUWKKISRHRSDOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  芦竹碱 、 4-(4-chloro-benzyl)-piperidin-4-ol 在 吡啶 作用下， 生成 1-((1H-indol-3-yl)methyl)-4-(4-chlorobenzyl)piperidin-4-ol
  参考文献：
  名称：

  Analogues of the dopamine D2 receptor antagonist L741,626: Binding, function, and SAR

  摘要：

  A series of analogues of the dopamine D2 receptor antagonist L741,626 were synthesized and evaluated for binding and function at D2 family receptor subtypes. Several analogues showed comparable binding profiles to the parent ligand, however, in general, chemical modification served to reduce D2 binding affinity and selectivity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.10.076
• 作为产物：
  描述：

  N-乙氧羰基-4-哌啶酮 在 氢氧化钾 、 magnesium 作用下， 以 乙醚 、 乙醇 为溶剂， 反应 38.0h， 生成 4-(4-chloro-benzyl)-piperidin-4-ol
  参考文献：
  名称：

  Design, Synthesis, and Evaluation of Metabolism-Based Analogues of Haloperidol Incapable of Forming MPP+-like Species

  摘要：

  The long-term, irreversible, Parkinsonism-like side effects of haloperidol have been speculated to involve several mechanisms. More recently, it has been speculated that the metabolic transformation to MPP+-like species may contribute to the Parkinsonism-like side effects. Because BCPP+ and its reduced analogue have been shown to possess the potential to destroy dopamine receptors in the nigrostriatum, we have designed new analogues of haloperidol lacking the structural features necessary to form neurotoxic quaternary species but retaining their dopamine-binding capacity. The most potent agent at the D2 receptor, the homopiperidine analogue 11, was found to be equipotent to haloperidol. It was also of interest to identify analogues with DA binding profiles similar to that of clozapine at the dopamine receptor subtypes. Evaluation of the proposed agents shows that the ratio of D2 to D4 (2) binding of clozapine was mimicked by 7 [K-i(D2) = 33, K-i(D3) = 200, K-i(D4) = 11 nM; K-i(D2)/K-i(D4) = 3] and 9 [K-i(D2) = 44, K-i(D3) = 170, K-i(D4) = 24 nM; K-i(D2)/K-i(D4) = 2]. A preliminary in-vivo testing of compound 7 shows that its behavioral profile is similar to that of clozapine. This profile suggests that there is a need for further evaluation of these two synthetic agents and their enantiomers for efficacy and lack of catalepsy in animal models.

  DOI：

  10.1021/jm0301033

文献信息

• [EN] INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER<br/>[FR] DÉRIVÉ D'INDOLE ET USAGE POUR LE TRAITEMENT DU CANCER
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2005118587A1

  公开（公告）日：2005-12-15

  The present invention relates to a compound represented by the formula (I’) wherein A is a benzene ring optionally having substituents, R1, R2a and R3 are each a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, R1 and R2a may form a ring via X, when R1 and R2a form a ring via X, R1 and R2a are each a bond or a divalent C1-5 acyclic hydrocarbon group optionally having substituents, and X is a bond, an oxygen atom, an optionally oxidized sulfur atom or an imino group optionally having a substituent, provided that R1, R2a and X are not bonds at the same time, or a salt thereof, and an agent for inhibiting kinase (phosphorylation enzyme), which contains this compound or a prodrug thereof. The compound of the present invention has an inhibitory activity against kinase such as a vascular endothelial growth factor receptor (VEGFR) and the like, and is useful as an agent for the prophylaxis or threatment of cancer and the like.

  本发明涉及一种由式(I')表示的化合物，其中A是一个苯环，可选地具有取代基，R1、R2a和R3分别是氢原子，可选地具有取代基的碳氢基团或可选地具有取代基的杂环基团，R1和R2a可以通过X形成环，当R1和R2a通过X形成环时，R1和R2a分别是键或可选地具有取代基的二价C1-5非环烃基团，X是键，氧原子，可选地氧化的硫原子或可选地具有取代基的亚胺基团，前提是R1、R2a和X不同时为键，或其盐，以及含有该化合物或其前药的抑制激酶（磷酸化酶）的药剂。本发明的化合物对激酶如血管内皮生长因子受体（VEGFR）等具有抑制活性，并可用作预防或治疗癌症等疾病的药剂。
• [EN] SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED DISEASES<br/>[FR] DÉRIVÉS DE SULFONYLPIPÉRIDINE ET LEUR UTILISATION POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR UNE PROKINÉTICINE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013179024A1

  公开（公告）日：2013-12-05

  The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof : (I) in which m, n, W, X, Y, Z, R1, R2, R3 and R4 are as defined in the specification, for use in the treatment or prevention of a diseases o conition mediated by a prokineticin, such as psychiatric and neurological conitions.

  本发明提供了以下式（I）的化合物及其药学上可接受的盐：（I）其中m、n、W、X、Y、Z、R1、R2、R3和R4如规范中定义，用于治疗或预防由前动力素介导的疾病或状况，如精神疾病和神经病状。
• 4-hydroxy-piperidine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06359138B1

  公开（公告）日：2002-03-19

  The present invention relates to 4-hydroxy-piperidine derivatives of the general formula wherein X denotes —O—, —NH—, —CH2—, —CH═, —CHOH—, —CO—, —S—, —SO— or —SO2—; R1-R4 are, independently from each other, hydrogen, hydroxy, lower-alkyl-sulfonylamino, 1- or 2-imidazolyl or acetamido; R5-R8 are, independently from each other, hydrogen, hydroxy, lower-alkyl, halogen, lower-alkoxy, trifluoromethyl or trifluoromethyloxy; a and b may be a double bond, provided that when “a” is a double bond, “b” cannot be a double bond; n is 0-2; m is 1-3; p is 0 or 1 and to pharmaceutically acceptable addition salts thereof. Compounds of the present invention are NMDA(N-methyl-D-aspartate)-receptor subtype selective blockers, which can be used in mediating processes underlying development of CNS including learning and memory formation and function.

  本发明涉及一般式的4-羟基哌啶衍生物，其中X代表—O—、—NH—、—CH2—、—CH═、—CHOH—、—CO—、—S—、—SO—或—SO2—；R1-R4分别是氢、羟基、较低烷基磺酰胺基、1-或2-咪唑基或乙酰胺基；R5-R8分别是氢、羟基、较低烷基、卤素、较低烷氧基、三氟甲基或三氟甲氧基；a和b可以是双键，但是当“a”是双键时，“b”不能是双键；n为0-2；m为1-3；p为0或1；以及其药学上可接受的盐。本发明的化合物是NMDA（N-甲基-D-天冬氨酸）受体亚型选择性阻断剂，可用于调节包括学习和记忆形成与功能在内的中枢神经系统发育过程。
• [EN] AMINE-CONTAINING TRANSFECTION REAGENTS AND METHODS FOR MAKING AND USING SAME<br/>[FR] RÉACTIFS DE TRANSFECTION AMINÉS ET PROCÉDÉS DE FABRICATION ET D'UTILISATION ASSOCIÉS
  申请人：LIFE TECHNOLOGIES CORP

  公开号：WO2012068176A1

  公开（公告）日：2012-05-24

  There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.

  本文提供了一种新型含胺转染化合物及其制备和使用方法。这些化合物通常是通过将一级胺与不饱和化合物反应而获得的。本文还提供了使用含胺转染化合物与其他化合物结合以封装生物活性剂（如核酸）制备的转染复合物。还描述了使用转染复合物进行体内或体外传递生物活性剂的方法。本发明的转染复合物具有很高的效力，因此与已知的类似转染化合物相比，可以在相对较低的剂量下有效调节生物活性。
• Compounds inhibiting the aggregation of superoxide dismutase-1
  申请人：Lansbury Peter

  公开号：US20060194821A1

  公开（公告）日：2006-08-31

  The invention is directed to methods of inhibiting the rate at which superoxide dismutse-1 (SOD) aggregates using compounds that stabilize SOD dimers. The methods are useful in the study and therapy of amyotrophic lateral sclerosis. The invention also includes assays that can be used to identify compounds that stabilize dimers and SOD molecules that have been modified for use in these assays.

  本发明涉及使用稳定SOD二聚体的化合物来抑制超氧化物歧化酶-1（SOD）聚集的速率的方法。该方法在进行肌萎缩侧索硬化的研究和治疗中非常有用。本发明还包括可用于识别稳定二聚体化合物和已经改性用于这些测定的SOD分子的测定方法。